Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02044874 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 603
- Enrollment target
NCT02044874: Completed Phase 2 study, sponsored by Arena Pharmaceuticals.
NCT02044874 is a Phase 2 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 603 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (353% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02044874, a Phase 2 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 603 participants
- Enrollment target
Study Summary
In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.
Primary Outcome
Primary efficacy was assessed as the CO (carbon monoxide)-confirmed continuous abstinence rate for the last 4 weeks of treatment (Month 3: Weeks 9 through 12), defined as no reported smoking (not even a puff) or other nicotine use, verified by end expiratory CO levels \<= 10 ppm.
Interventions
- DRUG Placebo
- DRUG APD356-lorcaserin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT02044874 record still lists
NCT02044874 is an interventional study that assigns participants to a tested intervention. The registered 603 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (353% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02044874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02044874 about?
NCT02044874 is a clinical study titled "A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation". In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.
What is the current status of trial NCT02044874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 603 participants. The study started on 2014-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02044874?
The interventions under investigation include: Placebo (DRUG), APD356-lorcaserin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02044874?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02044874's enrollment target sits among peer trials
603 53rd of 2000 higher than 1,948 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia